Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Pernicious Anemia Diagnosis And Treatment Market Expected To Reach $2.08 Billion By 2030 At 6.6% CAGR
The market for diagnosing and treating pernicious anemia has experienced robust expansion lately. Projections indicate a rise from $1.51 billion in 2025 to $1.62 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.8%. Factors contributing to this expansion during the historical period include the elevated occurrence of infections contracted in healthcare settings, a dependence on traditional intravenous catheters, an increasing number of patients needing IV therapy, a scarcity of sophisticated safety catheters, and a fragmented healthcare system.
The market for pernicious anemia diagnosis and treatment is poised for significant expansion, projected to reach a valuation of $2.09 billion by 2030, reflecting a compound annual growth rate (CAGR) of 6.6% over the forecast period. This anticipated growth is fueled by several key factors, including innovations in safety intravenous (IV) catheter technologies, the escalating adoption of smart and antimicrobial catheters, a broadening scope of home healthcare services, a growing inclination towards integrated or closed IV systems, and a heightened demand for minimally invasive therapeutic administration. Within this forecast horizon, notable trends are emerging, such as the increased integration of AI-powered systems for guiding catheter insertion, a rise in the utilization of cloud-based platforms for monitoring IV therapy, continuous development in antimicrobial and smart catheter technologies, the growing incorporation of IoT-enabled devices for IV monitoring, and the increasing implementation of smart manufacturing processes for peripheral IV catheters.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24360&type=smp
Pernicious Anemia Diagnosis And Treatment Market Development Factors: Which Trends Are Supporting Demand?
The growing incidence of vitamin B12 insufficiency is anticipated to be a significant catalyst for market expansion within the diagnosis and treatment of pernicious anemia. This deficiency arises when an individual’s body fails to produce sufficient red blood cells due to a lack of this vital vitamin, resulting in manifestations like persistent tiredness, diminished strength, and neurological complications. The increasing tendency towards adopting vegan and vegetarian lifestyles, which often omit natural sources rich in vitamin B12, contributes to this deficiency, potentially leading to insufficient consumption without targeted supplementation. This deficiency directly influences the diagnostic and therapeutic approaches for pernicious anemia, as diminished B12 levels critically hinder red blood cell formation, prompting medical professionals to implement B12 supplementation as a principal and efficacious treatment. Illustratively, data presented by the UK’s National Health Service (NHS) in February 2023 indicated that deficiencies in both vitamin B12 and folate disproportionately affect the elderly, with approximately 10% of individuals aged 75 and above and 5% of those aged 65 to 74 experiencing these deficiencies. Consequently, the escalating occurrence of vitamin B12 deficiency is fueling the growth trajectory of the pernicious anemia diagnosis and treatment sector.
Pernicious Anemia Diagnosis And Treatment Market Segment Analysis: What Are The Major Market Categories?
The pernicious anemia diagnosis and treatment market covered in this report is segmented –
1) By Type: Complete Blood Count Test, Vitamin B12 Deficiency test, Intrinsic Factor Deficiency Test
2) By Treatment: Vitamin B12 Injections, Vitamin B12 Pills, Spray
3) By Route Of Administration: Injection, Oral, Intranasal
4) By End-User: Hospitals, Clinics, Diagnostic Centres, Other End-users
Subsegments:
1) By Complete Blood Count (CBC) Test: Red Blood Cell Count, Hemoglobin Concentration, Hematocrit Levels, Mean Corpuscular Volume (MCV), White Blood Cell Count, Platelet Count
2) By Vitamin B12 Deficiency Test: Serum Vitamin B12 Test, Methylmalonic Acid (MMA) Test, Homocysteine Test, Holotranscobalamin (Active B12) Test
3) By Intrinsic Factor Deficiency Test: Intrinsic Factor Antibody Test, Parietal Cell Antibody Test, Schilling Test, Gastrin Level Test
Pernicious Anemia Diagnosis And Treatment Market Transformation Trends: Which Innovations Are Driving Change?
Within the competitive landscape of the pernicious anemia diagnosis and treatment sector, key industry players are prioritizing the creation of novel approaches, exemplified by vitamin B12 maintenance therapy options designed to bolster patient engagement and facilitate effective long-term care for the condition. These therapeutic strategies for sustaining vitamin B12 involve consistent, continued administration of supplements, whether in the form of oral pills, injections, or nasal mists, all aimed at upholding appropriate B12 concentrations and averting the reappearance of symptoms linked to its deficiency. As an illustration, during February of 2024, Lupin Pharmaceuticals Inc., a pharmaceutical enterprise headquartered in India, introduced its cyanocobalamin nasal spray, delivering 500 mcg per spray, presenting a less intrusive method for vitamin B12 enrichment. This nasal spray offers a user-friendly and efficacious means for individuals diagnosed with pernicious anemia who encounter difficulties with traditional oral vitamin B12 supplements, thereby improving the body’s uptake of B12 and aiding in the control of vitamin B12 deficiencies, ultimately leading to better patient adherence and treatment results.
Pernicious Anemia Diagnosis And Treatment Market Leading Companies Driving Competitive Growth
Major companies operating in the pernicious anemia diagnosis and treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Lupin Limited, Eli Lilly and Company, DSM Nutritional Products AG, Bio-Rad Laboratories Inc., CSL Vifor Pharma, Par Pharmaceutical Companies Inc., AdvaCare Pharma, Monobind Inc., Merck KGaA, Abbott Laboratories, Siemens Healthineers AG, Ortho Clinical Diagnostics Inc., Quest Diagnostics Incorporated, Bio-Techne Corporation
Access The Complete Pernicious Anemia Diagnosis And Treatment Market Report:
Pernicious Anemia Diagnosis And Treatment Market Global Footprint: Which Region Holds Market Leadership?
North Americawas the largest region in the pernicious anemia diagnosis and treatment market in 2025. The regions covered in the pernicious anemia diagnosis and treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
